<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789360</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-004-104</org_study_id>
    <secondary_id>12 September 2008</secondary_id>
    <nct_id>NCT00789360</nct_id>
  </id_info>
  <brief_title>Staccato Loxapine Pulmonary Safety in Healthy Volunteers</brief_title>
  <official_title>Pulmonary Safety of Repeat Doses of Staccato® Loxapine for Inhalation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to assess the pulmonary safety of 2 inhaled doses of Staccato
      Loxapine within a day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The planned study is a multiple dose, double-blind, placebo-controlled, randomized,
      2-sequence, 2-period crossover study investigating pulmonary safety in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Largest Treatment Difference (Loxapine - Placebo) in Change in FEV1 From Baseline by Spirometry</measure>
    <time_frame>17 post-treatment time points (15 min to 32 hr)</time_frame>
    <description>The largest treatment difference (Loxapine - Placebo) across the 17 post-treatment time points (15 min to 32 hr) in FEV1 Change from Same-Period Baseline,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Largest Treatment Difference (Loxapine - Placebo) in Change in FVC From Baseline by Spirometry</measure>
    <time_frame>17 post-treatment time points (15 min to 32 hr)</time_frame>
    <description>The largest treatment difference (Loxapine - Placebo) across the 17 post-treatment time points (15 min to 32 hr) in FVC Change from Same-Period Baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Inhaled Placebo crossed over to Inhaled Loxapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Placebo, 2 inhalations, 8 hours apart; washout of at least 4 days; Inhaled Staccato Loxapine, 10 mg oses x 2, 8 hours apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Loxapine crossed over to Inhaled Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart; washout of at least 4 days; Inhaled Staccato Placebo, 2 inhalations, 8 hours apart;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Placebo</intervention_name>
    <description>Inhaled Staccato Placebo, 2 inhalations, 8 hours apart</description>
    <arm_group_label>Inhaled Loxapine crossed over to Inhaled Placebo</arm_group_label>
    <arm_group_label>Inhaled Placebo crossed over to Inhaled Loxapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Loxapine</intervention_name>
    <description>Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart</description>
    <arm_group_label>Inhaled Loxapine crossed over to Inhaled Placebo</arm_group_label>
    <arm_group_label>Inhaled Placebo crossed over to Inhaled Loxapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nonsmoker subjects in good general health with normal spirometry at screening AND
             baseline

        Exclusion Criteria:

          -  history of asthma, COPD, or any other acute or chronic pulmonary disease or
             bronchodilator use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northeast Medical Research, North Dartmouth, MA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northeast Medical Research</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <results_first_submitted>March 12, 2017</results_first_submitted>
  <results_first_submitted_qc>November 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2019</results_first_posted>
  <last_update_submitted>November 18, 2018</last_update_submitted>
  <last_update_submitted_qc>November 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Each investigator obtained approval from their IRB for their advertisements and other subject recruitment procedures</recruitment_details>
      <pre_assignment_details>At screening and before administration of Dose 1 in each treatment period, the following were confirmed: forced expiratory volume in 1 second (FEV1) ≥85% of predicted, forced vital capacity (FVC) ≥85% of predicted, and oxygen saturation by pulse oximetry (SpO2)
≥95% on room air.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Placebo / Loxapine</title>
          <description>Inhaled Staccato Placebo, 2 inhalations, 8 hours apart followed by Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Loxapine / Placebo</title>
          <description>Inhaled Staccato Loxapine, 10 mg oses x 2, 8 hours apart followed by Inhaled Staccato Placebo, 2 inhalations, 8 hours apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Placebo / Loxapine</title>
          <description>Inhaled Staccato Placebo, 2 inhalations, 8 hours apart followed by Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Loxapine / Placebo</title>
          <description>Inhaled Staccato Loxapine, 10 mg oses x 2, 8 hours apart followed by Inhaled Staccato Placebo, 2 inhalations, 8 hours apart</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" spread="13.65"/>
                    <measurement group_id="B2" value="28.7" spread="9.75"/>
                    <measurement group_id="B3" value="30" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Largest Treatment Difference (Loxapine - Placebo) in Change in FEV1 From Baseline by Spirometry</title>
        <description>The largest treatment difference (Loxapine - Placebo) across the 17 post-treatment time points (15 min to 32 hr) in FEV1 Change from Same-Period Baseline,</description>
        <time_frame>17 post-treatment time points (15 min to 32 hr)</time_frame>
        <population>Crossover Spirometry Population (all subjects receiving both inhaled loxapine and inhaled placebo)
LSM and CI statistics were based on the individual (within subject) differences between loxapine and placebo exposures</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Loxapine</title>
            <description>Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Staccato Placebo</title>
            <description>Inhaled Staccato Placebo, 2 inhalations, 8 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>The Largest Treatment Difference (Loxapine - Placebo) in Change in FEV1 From Baseline by Spirometry</title>
          <description>The largest treatment difference (Loxapine - Placebo) across the 17 post-treatment time points (15 min to 32 hr) in FEV1 Change from Same-Period Baseline,</description>
          <population>Crossover Spirometry Population (all subjects receiving both inhaled loxapine and inhaled placebo)
LSM and CI statistics were based on the individual (within subject) differences between loxapine and placebo exposures</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1042" lower_limit="-0.1776" upper_limit="-0.0310"/>
                    <measurement group_id="O2" value="-0.1025" lower_limit="-0.18099" upper_limit="-0.02393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The largest treatment difference (Loxapine - Placebo) in change in FEV1 from baseline by spirometry</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Maximum LS mean change difference</param_type>
            <param_value>0.0917</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.028</ci_lower_limit>
            <ci_upper_limit>0.212</ci_upper_limit>
            <estimate_desc>Maximum difference occurred at 10 hours</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Largest Treatment Difference (Loxapine - Placebo) in Change in FVC From Baseline by Spirometry</title>
        <description>The largest treatment difference (Loxapine - Placebo) across the 17 post-treatment time points (15 min to 32 hr) in FVC Change from Same-Period Baseline</description>
        <time_frame>17 post-treatment time points (15 min to 32 hr)</time_frame>
        <population>Crossover Spirometry Population (all subjects receiving both inhaled loxapine and inhaled placebo)
LSM and CI statistics were based on the individual (within subject) differences between loxapine and placebo exposures</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Loxapine</title>
            <description>Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Staccato</title>
            <description>Inhaled Staccato Placebo, 2 inhalation, 8 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>The Largest Treatment Difference (Loxapine - Placebo) in Change in FVC From Baseline by Spirometry</title>
          <description>The largest treatment difference (Loxapine - Placebo) across the 17 post-treatment time points (15 min to 32 hr) in FVC Change from Same-Period Baseline</description>
          <population>Crossover Spirometry Population (all subjects receiving both inhaled loxapine and inhaled placebo)
LSM and CI statistics were based on the individual (within subject) differences between loxapine and placebo exposures</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.271" lower_limit="-0.370" upper_limit="-0.172"/>
                    <measurement group_id="O2" value="-0.149" lower_limit="-0.264" upper_limit="-0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Maximum LS mean change difference</param_type>
            <param_value>-0.154</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.290</ci_lower_limit>
            <ci_upper_limit>-0.019</ci_upper_limit>
            <estimate_desc>Greatest difference occurred at 9 hours after Dose 1</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment</time_frame>
      <desc>Adverse events (AEs) were assessed predose and at 16 pre-specified time points for the 24-hour period after dosing, as well as whenever spontaneously reported by the subjects or study staff</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
Inhaled Placebo: Inhaled Staccato Placebo, 2 inhalations, 8 hours apart</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Loxapine</title>
          <description>Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart
Inhaled Loxapine: Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive VP, Research &amp; Development, Regulatory &amp; Quality</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7071</phone>
      <email>ClinicalTrialsInfo@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

